

Amarantus Bioscience Holdings, Inc.
Form 8-K
October 15, 2013

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **October 14, 2013**

AMARANTUS BIOSCIENCE HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of
incorporation or organization)

333-148922

(Commission File Number)

26-0690857

IRS Employer

Identification No.)

675 Almanor Ave

94085

Sunnyvale, CA

(Address of Principal Executive Offices) (Zip Code)

(408) 737-2734

Edgar Filing: Amaranthus Bioscience Holdings, Inc. - Form 8-K

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act

- Soliciting material pursuant to Rule 14a-12 under the Exchange Act

- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01

Other Events.

In May 2012, a clinical study entitled “Multivariate analysis of differential lymphocyte cell cycle activity in Alzheimer’s disease” with respect to the LymPro test was published in the scientific journal *Neurobiology of Aging*. A copy of the report is furnished as Exhibit 99.1 to this Current Report on Form 8-K. On October 14, 2013, Amaranthus Bioscience Holdings, Inc. released a press release announcing positive analytical performance data for LymPro Test® for Alzheimer’s Disease. A copy of the press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information disclosed under this Item 8.01, including Exhibits 99.1 and 99.2 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
--------------------	--------------------

- | | |
|------|---|
| 99.1 | Clinical study entitled “Multivariate analysis of differential lymphocyte cell cycle activity in Alzheimer’s disease” |
| 99.2 | Press Release of Amaranthus Bioscience Holdings, Inc. dated October 14, 2013. |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**AMARANTUS BIOSCIENCE
HOLDINGS, INC.**

Date: October 15, 2013 By: */s/ Gerald E. Commissiong*
Name: Gerald E. Commissiong

Edgar Filing: Amaranthus Bioscience Holdings, Inc. - Form 8-K

Title: Chief Executive Officer